10-Q/A: PreAxia Health Amends Q1 Report, Bolsters Equity with Debt Conversion

PreAxia Health Care Payment Systems Inc. filed an amended quarterly report, correcting outstanding share counts and detailing significant debt-to-equity conversions and capital raises.

Summary

• The company filed an amendment to its Form 10-Q for the period ended August 31, 2025, to correct the outstanding shares on the cover page to 54,314,782 and shares issued to settle stock subscriptions in Note 11 to 34,547,084.
• PreAxia Health Care Payment Systems Inc. reported a net comprehensive loss of $874,906 for the three months ended August 31, 2025, a significant increase from $4,627 for the same period in 2024.
• Operating expenses surged to $875,203 for the three months ended August 31, 2025, compared to $4,627 in the prior year, primarily due to increased consulting, research and development, and management costs.
• The company's cash balance improved to $130,285 as of August 31, 2025, from $0 as of May 31, 2025.
• Shareholders' equity shifted from a deficit of ($2,341,169) as of May 31, 2025, to a positive equity of $427,322 as of August 31, 2025.
• Working capital deficit significantly improved from ($2,341,169) as of May 31, 2025, to ($232,678) as of August 31, 2025.
• The company converted $1,525,577 in related party debt (promissory note of $466,817 and convertible note of $1,058,760 from Tom Zapatinas) into 15,255,770 shares of common stock at $0.10 per share.
• Stock subscriptions totaling $1,800,000 were issued for services (16,500,000 shares for an Independent Contractor Agreement and 1,500,000 shares for consulting services), with 40% recognized as expense and 60% as prepaid expenses.
• A private placement in August 2025 raised $200,000 from the sale of 800,000 shares of common stock, which were issued in October 2025.
• Management identified a substantial doubt about the company's ability to continue as a going concern, citing a lack of significant cash, material assets, operations, or sufficient revenue to cover operating costs.
• Disclosure controls and procedures were deemed not effective as of August 31, 2025.

Sentiment

Score: 3

Explanation: While the company successfully converted significant debt to equity and raised some capital, improving its balance sheet, the core operational performance shows a dramatic increase in losses and expenses with no revenue. The explicit 'going concern' doubt and ineffective disclosure controls indicate severe underlying issues, outweighing the positive financing activities.

Positives

• Cash and cash equivalents increased significantly to $130,285 as of August 31, 2025, from $0 as of May 31, 2025.
• Shareholders' equity improved substantially, moving from a deficit of ($2,341,169) to a positive $427,322.
• Total liabilities decreased from $2,341,169 as of May 31, 2025, to $722,963 as of August 31, 2025, primarily due to debt conversions.
• Working capital deficit improved by over $2.1 million, from ($2,341,169) to ($232,678).
• Successfully converted $1,525,577 in related party debt into equity, reducing financial obligations.
• Raised $200,000 through a private placement of common stock, providing additional working capital.

Negatives

• Net comprehensive loss dramatically increased to $874,906 for the three months ended August 31, 2025, from $4,627 in the prior year.
• Total operating expenses surged to $875,203, an increase of $870,576 compared to the same period last year.
• The company continues to report $0 revenue, indicating products are still in the development stage with no commercialization.
• Accumulated deficit increased to ($6,085,524) as of August 31, 2025, from ($5,210,390) as of May 31, 2025.
• Disclosure controls and procedures were evaluated as not effective as of August 31, 2025.
• A substantial doubt exists about the company's ability to continue as a going concern.

Risks

• Substantial doubt about the ability to continue as a going concern due to lack of significant cash, material assets, operations, or sufficient revenue to cover operating costs.
• Dependence on developing additional sources of capital and ultimately achieving profitable operations.
• No assurance that additional financing will be available when needed or on commercially reasonable terms.
• Inability to meet obligations and potential cessation of business operations if additional financing is not secured.
• Potential for significant dilution for current shareholders if additional equity securities are issued.
• Increased liabilities and future cash commitments if commercial loans are obtained.
• Products are in the development stage, with no current revenue generation.
• Ineffective disclosure controls and procedures as of August 31, 2025, posing risks to financial reporting integrity.
• Reliance on officers or principal shareholders for advances or loans to cover legal, accounting, and administrative costs.

Future Outlook

The company plans to raise an estimated $1,000,000 over the next twelve months to cover $300,000 for arms-length creditors and $700,000 to complete its business plan. This capital is expected to be raised through private placements of equity securities or loans. The company intends to penetrate healthcare processing markets in Canada, the United States, and worldwide by developing innovative products, building strategic alliances with health insurance companies and governments, and filling senior management, sales, administrative, and engineering positions. Procedures to assess, identify, and manage material cybersecurity risks will be created in the upcoming year.

Management Comments

• "The Company's ability to continue as a going concern is dependent upon its ability to develop additional sources of capital and to ultimately achieve profitable operations."
• "Currently, the Company does not have significant cash or other material assets, nor does it have operations or a source of revenue sufficient to cover its operating costs and allow it to continue as a going concern."
• "The Company hopes to be able to attract suitable investors for our business plan, which will not require us to use our cash."
• "There can be no assurance that the Company will be successful in this situation."
• "Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing, or cause substantial dilution for our shareholders, in the case of equity financing."
• "Our cash and cash equivalents will not be sufficient to meet its working capital requirements for the next twelve-month period."
• "We will not initially have any cash flow from operating activities as we are in the startup stage."

Industry Context

The company operates in the emerging health payment market, specifically targeting opportunities tied to the growth of Health Spending Accounts (HSAs). This market is driven by a rapid shift from traditional payment models to consumer-directed healthcare, creating significant opportunities for financial services and insurance industries. Studies suggest HSAs in the US reached $122.8 billion in assets in 2023 and 33.9 million consumers in 2022, indicating substantial growth. The company also notes the continued growth of the Canadian group insurance industry as an emerging opportunity for innovative health payment services, with Canadian businesses embracing new healthcare financing vehicles.

Management Changes

Corporate Governance

Related Party Transactions

• Tom Zapatinas (CEO and Director) had accrued officer compensation of $420,000 and related payroll taxes of $68,725 as of August 31, 2025.
• Tom Zapatinas earned $30,000 for consulting services during the three months ended August 31, 2025.
• Advances payable due to Tom Zapatinas totaled $100,438 as of August 31, 2025.
• A promissory note of $466,817 due to Tom Zapatinas was converted to a stock subscription for 4,668,170 shares on June 30, 2025.
• A convertible note payable of $1,058,760 due to Tom Zapatinas was converted to a stock subscription for 10,587,600 shares on June 30, 2025.
• Pavel Bondarev (Director and CEO of Zane Inc.) had accrued officer compensation of $12,661 as of August 31, 2025.
• Pavel Bondarev earned $20,000 for management services during the three months ended August 31, 2025, and received a stock subscription worth $660,000.

Stakeholder Impact

• Shareholders face potential significant dilution from future equity financing, but current debt-to-equity conversions have improved the balance sheet structure.
• Employees and contractors (including management) are receiving compensation through stock subscriptions, aligning their interests with company performance but also exposing them to equity risk.
• Creditors have seen a significant portion of related party debt converted to equity, reducing the company's immediate financial obligations but shifting risk to equity holders.
• Customers (future) may benefit from the continued development of healthcare payment processing and personal financial management products, assuming the company achieves commercialization.

Next Steps

• Raise an estimated $1,000,000 in additional capital over the next twelve months to fund operations and business plan completion.
• Penetrate healthcare processing markets in Canada, the United States, and globally by continuing to develop innovative products and services.
• Build a network of strategic alliances with health insurance companies, governments, and other partners in various vertical markets.
• Fill senior management, sales, administrative, and engineering positions.
• Create procedures to assess, identify, and manage material risks from cybersecurity threats in the upcoming year.

Key Dates

Recommendation

Despite the positive shift in shareholders' equity and reduction in liabilities due to debt conversions and a small capital raise, the company's fundamental operational performance is severely distressed. The net comprehensive loss surged by over 18,000% year-over-year, with zero revenue and a massive increase in operating expenses. The explicit 'going concern' warning, coupled with ineffective disclosure controls, indicates profound financial and governance risks. The company's products are still in the development stage, offering no immediate path to revenue. The reliance on future capital raises, which may cause significant dilution, and the lack of assurance for obtaining such funds, make this a highly speculative and risky investment. A seasoned investor would view the operational burn rate and the going concern risk as paramount, overshadowing any balance sheet improvements from financing activities.

Keywords

Healthcare payments, Financial management, Health spending accounts, HSA, Zane Inc, PreAxia, SEC filing, 10-Q/A, Capital raise, Debt conversion, Fintech, Software development